Daix (France), New York City (New York, United States), May 13, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the presentation of two abstracts at the upcoming annual congress of the European Association for the Study of the Liver, EASL Congress 2026, to be held from May 27 to 30, 2026 in Barcelona.
Details of the presentations are as follow:
| Abstract title: | Lanifibranor-induced improvements in histological parameters and cardiometabolic markers in MASH are independent of weight change and closely associated with adiponectin induction |
| Publication number: | FRI-189 |
| Type of presentation: | Poster presentation |
| Authors: | Mary E Rinella, Guillaume Wettstein, Philippe Huot-Marchand, Jason Campagna, Sven Francque, Manal F. Abdelmalek |
| Date: | May 29, 2026 |
| Abstract title: | Ultrastructural assessment of liver sinusoidal endothelial cell capillarisation in metabolic dysfunction-associated steatotic liver disease and its modulation by lanifibranor |
| Publication number: | SAT-117-YI |
| Type of presentation: | Poster presentation |
| Authors: | Shivani Chotkoe, Guillaume Wettstein, Joris De Man, Sofie Thys, Isabel Pintelon, Yang Lu, Nateneal Beyene, Jean-Louis Junien, Denise van der Graaff, Benedicte De Winter, Winnok H. De Vos, Luisa Vonghia, Wilhelmus J. Kwanten, Sven M. Francque |
| Date: | May 30, 2026 |
In addition, Inventiva will be present at the Congress at booth No. 35.
About Lanifibranor
Lanifibranor, Inventiva's most advanced drug candidate, is an orally administered small molecule whose mechanism of action consists of inducing antifibrotic, anti-inflammatory effects as well as beneficial vascular and metabolic changes by activating all three-peroxisome proliferator-activated receptor ("PPAR") isoforms. PPARs are well-characterized nuclear receptors that regulate gene transcription. Lanifibranor is a PPAR agonist designed to activate all three PPAR isoforms in a moderate and equipotent manner, with balanced activation of PPARa and PPARd, and partial activation of PPAR?. While other PPAR agonists exist that target one or two PPAR isoforms, lanifibranor is the only pan-PPAR agonist currently in clinical development. The Company believes that lanifibranor's moderate and balanced pan-PPAR modulator profile also contributes to the favorable safety and tolerability profile that has been observed in the clinical trials and preclinical studies in which it has been evaluated. The U.S. Food and Drug Administration (FDA) has granted lanifibranor both Breakthrough Therapy and Fast Track designations for the treatment of MASH.
About Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of an orally administered small molecule for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.
Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). http://www.inventivapharma.com
Contacts
| Investor Relations David Nikodem: IR@inventivapharma.com Patricia L. Bank: patti.bank@icrhealthcare.com | Media Relations Pascaline Clerc: media@inventivapharma.com Alexis Feinberg: inventivapr@icrhealthcare.com |
Attachment
- Inventiva - PR - Abstracts EASL 2026 - EN - 05 13 2026
